Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Access Pharmaceuticals was incorporated in 1974 as Chemex Corporation, and in 1983, changed its name to Chemex Pharmaceuticals Inc. In January 1996, Chemex merged with Access Pharmaceuticals Inc to create the existing company.

Access is an emerging pharmaceutical company focused on the development and commercialisation of advanced drug-delivery systems to improve the clinical outcome for both novel and marketed drugs. The company is developing both novel low-development risk product candidates and technologies with major product opportunities utilising value added advanced delivery technologies.

An integral part of the Access business strategy is the cost effective development of product candidates. To achieve this objective, the company conducts limited research and discovery activities, instead it acquires or licenses technologies or product candidates.